Clinical and genetic characterization of Uruguayan patients suffering from muscular pathology of unknown etiology. Preliminary results

Abstract

treatment (p = 0.070). Their 22 PGIC scores showed that 64% improved; 18% worsened. Among the 8/31 (26%) IVIG-responders (N30% pain reduction), pain dropped from 7.1 ± 1.6 to 3.2 ± 2.3, and half of their universally abnormal baseline AFTs normalized. 40% reported PGIC improvement. Infusion reactions were typical and manageable, including one hemolytic anemia and several vein thromboses. Conclusion: This preliminary evidence of IVIG efficacy and safety in select SFPN patients provides rationale and effect sizes for larger studies.